Tags

Type your tag names separated by a space and hit enter

The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
Int Braz J Urol. 2013 Sep-Oct; 39(5):657-62.IB

Abstract

PURPOSE

We aimed to compare the effect and feasibility of a combined therapy with tamsulosin hydrochloride plus meloxicam, and tamsulosin hydrochloride alone in patients with benign prostate hyperplasia symptoms and impact on nocturia and sleep quality.

MATERIALS AND METHODS

Four hundred male patients were included in this study between 2008 and 2011. Patients were randomly divided into two groups: one received tamsulosin hydrochloride 0.4 mg (Group 1, 200 patients) and the other tamsulosin hydrochloride 0.4 mg plus meloxicam 15 mg (Group 2, 200 patients) prospectively. Patients were evaluated for benign prostate hyperplasia (BPH) symptoms according to the American Urological Association clinical guidelines and sleep quality according to Pittsburgh Sleep Quality Index (PSQI). Patients were reevaluated after three months of treatment. The International Prostatic Symptom Score (IPSS), IPSS-Quality of Life (IPSS-QoL), maximal urinary flow rates (Qmax), average urinary flow rates (AFR), post void residual urine volumes (PVR), nocturia and Pittsburgh Sleep Quality Score (PSQS) were recorded at baseline and after three months.

RESULTS

Mean age was 63.3 ± 6.6 and 61.4 ± 7.5 years in groups 1 and 2, respectively (p = 0.245). There were no statistically significant differences between both groups. Also, baseline prostate specific antigen (PSA), prostate volume, creatinine, International Prostatic Symptom Score (IPSS), IPSS-Quality of Life (IPSS-QoL), maximal urinary flow rates (Qmax), average urinary flow rates (AFR), post void residual urine volumes (PVR), nocturia and Pittsburgh Sleep Quality Score (PSQS) were similar in both groups. In addition, the total IPSS, IPSS-QoL, PVR, nocturia, and PSQS were significantly lower in Group 2 compared with Group 1 after treatment (p < 0.05). Qmax and AFR were higher significantly in Group 2 compared with Group 1 after treatment (p < 0.05).

CONCLUSIONS

Cyclooxygenase (COX)-2 inhibitors in combination with an alpha blocker may decrease benign prostatic hyperplasia symptoms and increase sleep quality without serious side effects.

Authors+Show Affiliations

Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

24267123

Citation

Gorgel, Sacit Nuri, et al. "The Effect of Combined Therapy With Tamsulosin Hydrochloride and Meloxicam in Patients With Benign Prostatic Hyperplasia Symptoms and Impact On Nocturia and Sleep Quality." International Braz J Urol : Official Journal of the Brazilian Society of Urology, vol. 39, no. 5, 2013, pp. 657-62.
Gorgel SN, Sefik E, Kose O, et al. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality. Int Braz J Urol. 2013;39(5):657-62.
Gorgel, S. N., Sefik, E., Kose, O., Olgunelma, V., & Sahin, E. (2013). The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality. International Braz J Urol : Official Journal of the Brazilian Society of Urology, 39(5), 657-62. https://doi.org/10.1590/S1677-5538.IBJU.2013.05.07
Gorgel SN, et al. The Effect of Combined Therapy With Tamsulosin Hydrochloride and Meloxicam in Patients With Benign Prostatic Hyperplasia Symptoms and Impact On Nocturia and Sleep Quality. Int Braz J Urol. 2013 Sep-Oct;39(5):657-62. PubMed PMID: 24267123.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality. AU - Gorgel,Sacit Nuri, AU - Sefik,Ertugrul, AU - Kose,Osman, AU - Olgunelma,Vural, AU - Sahin,Evren, PY - 2013/01/23/received PY - 2013/09/18/accepted PY - 2013/11/26/entrez PY - 2013/11/26/pubmed PY - 2014/4/22/medline SP - 657 EP - 62 JF - International braz j urol : official journal of the Brazilian Society of Urology JO - Int Braz J Urol VL - 39 IS - 5 N2 - PURPOSE: We aimed to compare the effect and feasibility of a combined therapy with tamsulosin hydrochloride plus meloxicam, and tamsulosin hydrochloride alone in patients with benign prostate hyperplasia symptoms and impact on nocturia and sleep quality. MATERIALS AND METHODS: Four hundred male patients were included in this study between 2008 and 2011. Patients were randomly divided into two groups: one received tamsulosin hydrochloride 0.4 mg (Group 1, 200 patients) and the other tamsulosin hydrochloride 0.4 mg plus meloxicam 15 mg (Group 2, 200 patients) prospectively. Patients were evaluated for benign prostate hyperplasia (BPH) symptoms according to the American Urological Association clinical guidelines and sleep quality according to Pittsburgh Sleep Quality Index (PSQI). Patients were reevaluated after three months of treatment. The International Prostatic Symptom Score (IPSS), IPSS-Quality of Life (IPSS-QoL), maximal urinary flow rates (Qmax), average urinary flow rates (AFR), post void residual urine volumes (PVR), nocturia and Pittsburgh Sleep Quality Score (PSQS) were recorded at baseline and after three months. RESULTS: Mean age was 63.3 ± 6.6 and 61.4 ± 7.5 years in groups 1 and 2, respectively (p = 0.245). There were no statistically significant differences between both groups. Also, baseline prostate specific antigen (PSA), prostate volume, creatinine, International Prostatic Symptom Score (IPSS), IPSS-Quality of Life (IPSS-QoL), maximal urinary flow rates (Qmax), average urinary flow rates (AFR), post void residual urine volumes (PVR), nocturia and Pittsburgh Sleep Quality Score (PSQS) were similar in both groups. In addition, the total IPSS, IPSS-QoL, PVR, nocturia, and PSQS were significantly lower in Group 2 compared with Group 1 after treatment (p < 0.05). Qmax and AFR were higher significantly in Group 2 compared with Group 1 after treatment (p < 0.05). CONCLUSIONS: Cyclooxygenase (COX)-2 inhibitors in combination with an alpha blocker may decrease benign prostatic hyperplasia symptoms and increase sleep quality without serious side effects. SN - 1677-6119 UR - https://www.unboundmedicine.com/medline/citation/24267123/The_effect_of_combined_therapy_with_tamsulosin_hydrochloride_and_meloxicam_in_patients_with_benign_prostatic_hyperplasia_symptoms_and_impact_on_nocturia_and_sleep_quality_ L2 - http://www.brazjurol.com.br/september_october_2013/Gorgel_657_662.htm DB - PRIME DP - Unbound Medicine ER -